Kwa. Bang et al., Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens, BLOOD, 95(5), 2000, pp. 1735-1742
Recipient IgG immunity against leukoreduced donor platelets is dependent on
indirect T-cell allorecognition and is suppressed in vivo by inhibitors (a
minoguanidine, AMG) of inducible nitric oxide synthase (iNOS), To examine r
ecipient processing pathways of donor platelet antigens, enriched macrophag
es (antigen-presenting cells [APC]) from BALB/c (H-2(d)) mice were pulsed w
ith allogeneic C57BL/6 (H-2(b)) platelets and transfused weekly into naive
BALB/c mice. Platelet-pulsed APC stimulated IgG antidonor antibody producti
on in 45% of recipients by the second transfusion and in 100% by the sixth
transfusion; this response was enhanced by pulsing in the presence of inter
feron-gamma. By the sixth transfusion, high-titer IgG1 (mean titer 4990) an
d IgG2a (1933) isotypes specific for donor major histocompatibility complex
(MHC) class I antigens were detected. Platelet pulsing in the presence of
AMG or colchicine significantly inhibited the ability of APC to stimulate I
gG alloantibodies; only 50% (P < .005) and 20% (P < .0001) of recipients, r
espectively, produced antibodies by the sixth transfusion. AMG inhibition w
as reversed by the addition of L-arginine, the substrate for iNOS, In contr
ast, pulsing in the presence of chloroquine, the proteasome inhibitory pept
ide MG115, or Brefeldin A enhanced APC immunity (70-100% of recipients anti
body positive by the second transfusion [P < .05]); these agents allowed th
e pulsed APC to stimulate IgG2a but inhibited IgG1 production and this corr
elated with a reduction in serum interleukin (IL)-4 levels, The results sug
gest that for donor platelet antigens to stimulate IgG alloantibodies, reci
pient APC use the essential generation of nitric oxide and a noncytosolic,
pH-independent processing pathway, which can be exploited as an effective i
mmunotherapy target to further inhibit alloimmunization against leukoreduce
d platelets, (C) 2000 by The American Society of Hematology.